ArticleADMET & DMPK2026
Enhanced anti-inflammatory and antibacterial efficacy of a novel gum ghatti-infused polymeric film for ocular drug delivery.
Article in ADMET & DMPK, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Ocular inflammation is a key challenge after ocular surgery, and resistance has developed in the bacterial strain. Primarily, the short residence time of the ocular formulation makes it more effective in treating and alleviating inflammation. Experimental approach: In this study, a moxifloxacin-incorporated gum ghatti-infused poly(vinyl alcohol-chitosan) polymeric film was developed by solvent casting. Various properties of the ocular composite film, including mucoadhesiveness, strength profile, and crystal size, were evaluated. Key results: The prepared composite film exhibited a red-yellow hue. XRD and DSC analyses revealed that the drug in the formulation is amorphous. The release profile reduces the release rate and follows both Fickian- and non-Fickian-mediated pathways. A clear zone of inhibition was observed against both Gram-negative ( Conclusion: Based on the foregoing discussion, the formulation shows potential for treating ocular conjunctivitis and can be safely used for pink eye, bacterial conjunctivitis, or allergic conjunctivitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.